Results 301 to 310 of about 717,961 (381)
ARID1A, a SWI/SNF complex component, is frequently mutated in colorectal cancer (CRC). CRC with ARID1A/TP53 concurrent mutations shows marked sensitivity to WEE1 inhibition. ARID1A loss induces R‐loop‐mediated replication stress, impairs ATF3 transcription, and amplifies WEE1i‐induced DNA damage, suggesting a promising therapeutic vulnerability ...
Chi Zhang +17 more
wiley +1 more source
Real-World Clinical Usage and Safety Profile of Intravitreal Pegcetacoplan in Age-Related Macular Degeneration-Associated Geographic Atrophy. [PDF]
Abbas A, Singaravelu J, Fein JG.
europepmc +1 more source
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
Assessing Quality of Life and Patient-Reported Outcomes in Diabetic Macular Edema Treated With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Agents: A Systematic Review and Meta-Analysis. [PDF]
Shameem FJ +6 more
europepmc +1 more source
A post‐stroke perivascular niche of microglia characterized by low expression of M2 markers and elevated glycolysis, oxidative phosphorylation (OXPHOS), and phagocytic activity is identified, which is termed stroke‐activated vascular‐associated microglia (stroke‐VAM).
Yanan Li +8 more
wiley +1 more source
Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice. [PDF]
Bae EB +11 more
europepmc +1 more source
FPD‐GELNs co‐deliver Su and bioactive components. This active‐passive dual‐targeting strategy suppresses the progression of RCC through the following mechanisms: 1) inhibition of the PI3K‐Akt signaling pathway; 2) downregulation of ABCB1/P‐gp to enhance the chemosensitivity of RCC to Su; and 3) reprogramming of macrophages toward M1 polarization and ...
Haoyu Xu +8 more
wiley +1 more source
Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy. [PDF]
Shi F +8 more
europepmc +1 more source
This study develops a Mg‐H‐SPEEK implant with NIR‐switchable immunomodulatory properties. Under NIR, it promotes M1 macrophages for antibacterial action; without NIR, it induces M2 reprogramming to enhance tissue healing. This dual‐function material offers a smart strategy for reducing infection and improving integration in percutaneous implants ...
Yinghao Wu +9 more
wiley +1 more source

